Ingenix.ai Secures €9M to Advance Multimodal AI Foundation Model for Simulating Clinical Trials

Warsaw-based biotech company Ingenix.ai has closed a €9 million funding round to support the development of its proprietary foundation model for simulating clinical trials. Investors include Inovo, OTB Ventures, and the International Finance Corporation (IFC). The startup, founded in 2023 by Adam Dancewicz and Piotr Surma, builds AI systems designed to model biological processes across molecular, cellular, tissue, and population levels.

Ingenix.ai’s platform integrates genomic, transcriptomic, proteomic, imaging, and phenotypic data to create simulations of clinical trials on digital twins. According to the company, its generative AI model supports low-level biological reasoning tasks—such as molecular docking and pathway activation—at speeds reportedly orders of magnitude faster than current molecular modeling tools. These granular predictions inform higher-level projections of clinical endpoints and adverse events.

The model incorporates a chain-of-thought prompting framework and supports interaction via natural language, allowing researchers to probe the rationale behind predictions. The approach is intended to support use cases such as first-in-class drug evaluation, endpoint forecasting, and early triage of drug candidates prior to human trials.

The funding will be used to expand Ingenix.ai’s AI and biology research teams, scale its infrastructure, and integrate additional datasets. The company’s broader goal is to serve clinical development teams, preclinical drug selectors, and R&D strategists with a co-pilot system for decision-making in clinical research. The founders and technical team include former developers of Applica’s multimodal LLMs (acquired by Snowflake), contributors to LongLLaMA, and AI researchers with ties to DeepMind.

Topics: Startups & Deals